Aprea Therapeutics

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Boston, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2 study evaluating the efficacy of the company's candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37% of patients.

Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia

Iterum Therapeutics Plc

Predictive Oncology Inc

Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?

Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded

Kindred Biosciences

Catabasis Pharmaceuticals

Inhibikase Therapeutics

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest biopharma movers on Wednesday. Kindred Flies On Buyout: Kindred announced an agreement to be bought by Elanco Animal Health Incorporated (NYSE: ELAN) for $9.25 per share, or approximately $440 million.

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. The post APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today appeared first on InvestorPlace.

APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today

The stock price of Aprea Therapeutics, Inc. (NASDAQ: APRE) increased by over 40% during intraday trading this morning. This is why it happened.

APRE Stock Price Increases Over 40%: Why It Happened

Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate. The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML.

Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading higher by 46% at $7.07 after the company announced the Phase 1/2 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met the complete remission (CR) primary efficacy endpoint. According to the press release, in 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37% and the composite response rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%.

Why Aprea Therapeutics Shares Are Surging Today

BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice President and Chief Business Officer, will present a corporate update at the 2021 Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 3:45 p.m. ET.

Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit

BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal C. Attar, Senior Vice President and Chief Medical Officer, will participate in a fireside discussion at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 2:30 p.m. ET.

Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months ended March 31, 2021 and provided a business update.

Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D Day at 1:00 p.m. ET on Thursday, April 22, 2021.

Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

STOCKHOLM, SWEDEN – April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therapeutics' drug candidate eprenetapopt for the treatment of acute myeloid leukemia (AML). KDev Investments, a company jointly owned by Karolinska Development and Rosetta Capital, holds 8 percent of the shares in Aprea Therapeutics, which is listed on Nasdaq Global Select Market in the USA.

Karolinska Development's portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AML

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to eprenetapopt for treatment of AML.

Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)

Immutep Ltd

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia. Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics.

What's Going On With APRE Stock And IMMP Stock Today?

BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year ended December 31, 2020 and provided a business update.

Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, will present a corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. ET.

Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

Shares of Aprea Therapeutics Inc (NASDAQ: APRE) have received a target price decrease from $34 to $6 from Morgan Stanley. These are the details.

APRE Stock Price: $6 Target By Morgan Stanley

Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.

Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal

Aprea Therapeutics Inc. (NASDAQ: APRE) stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatment for myelodysplastic syndromes (MDS).

Is Aprea Therapeutics Doomed?

BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS). The trial did not meet the predefined primary endpoint of complete remission (CR) rate.   Analysis of the primary endpoint at this data cut demonstrated a higher CR rate in the experimental arm receiving eprenetapopt with AZA versus the control arm receiving AZA alone, but did not reach statistical significance. In the intention-to-treat population of 154 patients, the CR rate in the eprenetapopt with AZA arm was 33.3% (95% CI: 23.1% - 44.9%) compared to 22.4% (95% CI: 13.6% - 33.4%) in the AZA alone arm (P = 0.13).

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The Company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS).

Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

Viking Therapeutics

Vaxart

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

3 Stocks with Jaw-Dropping Growth Potential

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.

News for Aprea Therapeutics Stock (APRE)